FindTrial
Sign In

The vasoconstrictor drugs in the treatment of the Hepatorenal syndrome. The randomized clinic end multicentric study. - (HRS) study

The vasoconstrictor drugs in the treatment of the Hepatorenal syndrome. The randomized clinic end multicentric study. - (HRS) study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-005014-13-IT
Enrollment
Unknown
Registered
2007-06-05
Start date
2006-07-17
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HRS Syndrome MedDRA version: 6.1 Level: PT Classification code 10019845

Interventions

Trade Name: GLIPRESSINA Pharmaceutical Form: Solution for injection INN or Proposed INN: telipressin Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Trade Name:

Sponsors

AZIENDA OSPEDALIERA DI PADOVA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: cirrotic patients age 18-75 Diagnosis of HRS type 1 or2 with plasmatic creatinin superior to 2,5 mg/dl Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: -hepatic K ,batteric infection with septic shock.Respiratory and heart failure.Presence of periferic arteriopaty.ischemic cardiomiopaty

Design outcomes

Primary

MeasureTime frame
Main Objective: valutation the efficacy and safety two treatment in the hepatorenal syndrome;Secondary Objective: -survival at 1 and 3 mounth -liver failure -liver function -PAO and FC -vasocostrictor parameters.;Primary end point(s): total recovery of renal function.—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026